Vortioxetine Versus Placebo for Major Depressive Disorder: A Comprehensive Analysis of the Clinical Trial Dataset
Clicks: 178
ID: 266911
2021
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
30.0
/100
178 views
56 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #94 of 273 articles by views in the journal of clinical psychiatry
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 273 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Prior meta-analyses have found vortioxetine to be efficacious for depression. Building on those findings, the present meta-analysis examined the effect that placebo response has on drug-placebo effect size in studies of vortioxetine treatment.
| Reference Key |
iovieno2021thevortioxetine
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Nadia Iovieno;George I. Papakostas;Anna Feeney;Maurizio Fava;Sanjay J. Mathew;Dan I. Iosifescu;James W. Murrough;Matthew Macaluso;Rebecca S. Hock;Manish K. Jha; |
| Journal | the journal of clinical psychiatry |
| Year | 2021 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.